human acyl-cholesterol acyltransferase inhibitors [16] . According to the above information's and in continuation of our program of studying the chemistry of phenylpyrazole derivatives incorporated with other biologically active heterocycles such as pyrane, pyridine, imidiazole, benzimidiazole, tetrazole, thiazole and naphthaline was synthesized to see the additive effect of these heterocyclic rings towards the antitumor activities.
Experimental

Materials
All melting points were measured on an Electrothermal 9100 series digital melting point apparatus (Shimadzu, Japan). Microanalytical data were gathered with a Vario Elementar apparatus (Shimadzu). Elemental analyses of all compounds were within ± 0.4% of the theoretical values. The IR spectra (KBr) were recorded on a Perkin Elmer 1650 spectrometer (USA).
NMR and
13 C NMR spectra were recorded on a JEOL EX-300 and JEOL ECA-500 (Shimadzu) instruments. Chemical shifts were expressed in ppm relative to SiMe 4 as internal standard in DMSO-d 6 as a solvent. Mass spectra were recorded on a 70 eV Finnigan SSQ 7000 spectrometer (Thermo-Instrument System Incorporation, USA). The purity of the compounds was checked on aluminum plates coated with silica gel (Merck, Germany). Chemicals and solvents (Analar ≥ 99%) were purchased from Sigma-Aldrich (USA). Doxorubicin disks were supplied by the Pasteur Laboratory (Egypt).
3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-carboxaldhyde (2) was achieved by a reported method [17] General Procedure for the synthesis of
-[ 3 -( 4 -c h l o ro p h e n y l ) --p h e n y l -H -4 -acylpyrazole derivatives (3a, b)
A solution of methyl lithium in diethyl ether (5 mL), or vinyl magnesium bromide in THF (3 mL) and compound 2 (2.83 g, 10 mmol) in THF (15 mL) was stirred under liquid nitrogen (-78 ᵒC) for 1 h. Then catalytic amount of MnO 2 in chloroform (20 mL) was added and the reaction mixture was stirred at room temperature for appropriate time. The progress of the reaction was monitored by TLC after every 30 min. The mixture was cooled to room temperature and the obtained solid was filtrated off, washed with cold EtOH (15 mL), dried, and crystallized from ethanol.
1-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl] ethanone (3a)
White crystal in 70% yield; mp. 
A solution of 1-methyl imidiazole (3.5 mL), n-butyl lithium (2.5 mL), and compound 2 (2.83 g, 10 mmol) in THF (15 mL) was stirred under liquid nitrogen (-78 ᵒC) for 1h. and then catalytic amount of MnO 2 in chloroform (20 mL) was added. The reaction mixture was stirred at room temperature for 6 h. The progress of the reaction was monitored by TLC after every 30 min. The mixture was cooled to room temperature and the obtained solid was filtrated off, washed with cold EtOH (15 mL), dried, and crystallized from ethanol as orange powder in 69% yield; mp. 
1-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-(morpholin-4-yl)propan-1-one (5)
A mixture of compound 3b (3.08 g, 10 mmol) and morpholine (2.5 mL) was stirred under reflux in ethanol for 4 hours. The solvent was evaporated and the crude product was collected and crystallized from DMF, as a red powder in 65 % yield; mp. 220-222°C; IR (KBr, cm 
General Procedure for the synthesis of
A mixture of compound 2 (2.83 g, 10 mmol), aniline derivatives (namely 4-methyl aniline, 4-methoxy aniline, 4-nitro aniline and 4-chloroaniline respectively) (10 mmol), thioglycolic acid (10 mmol) was stirred under reflux in ethyl acetate for the appropriate time. Completion of the reaction was indicated by TLC monitoring. The reaction mixture was cooled to ambient temperature, and the crude solid residue was recrystallized from ethanol to afford pure crystals of the proper1,3-thiazolidin-4-one derivatives in 75-86% yields.
2-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-(4-tolyl)-1,3-thiazolidin-4-one (6a)
White 
2-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-(4-nirophenyl)-1,3-thiazolidin-4-one (6c)
3-(4-chlorophenyl)-2-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-1,3-thiazolidin-4-one (6d)
General Procedure for the synthesis of 3-benzyl-6-substituted-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine (7a-c)
A mixture of compound 2 (2.83 g, 10 mmol) and 2-aminopyridine derivatives (10 mmol) was stirred for 30 min. Water (30 ml) was added, followed by addition of phenyl acetylene (15 mmol). Then, Cu-Mn catalyst (10%) (1: 0.25) was added, and resulting mixture was refluxed at 100 ᵒC for 6 h. Completion of the reaction was monitored by TLC. The reaction mixture was filtered off and the residue washed with water. The product was crystalized from DMF, to obtain the desired products 7a-c 
3-benzyl-6-floro-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]imidazo[1,2-a]pyridine (7b)
Pale [1,2-a] 
3-benzyl-6-choro-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]imidazo
6-amino-4-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-5-cyano-4H-pyran-2-carboxylic acid (8)
A mixture of compound 2 (2.83 g, 10 mmol), pyruvic acid (7 ml, 10 mmol), and malononitrile (12 mmol) was dissolved in ethanol (50 mL). Fe 3 O 4 as a catalyst (0.05 g) was then added to this mixture. This mixture was stirred under reflux. The progress of reaction was monitored by TLC (7:3, n-hexane/ethyl acetate). Upon completion of the reaction, the mixture was cooled to room temperature. The remaining solution is concentrated to the product as a crude. This crude was crystallized from ethanol, as a gray powder in 67 % yield; mp: 220-222°C; IR (KBr, cm 
General Procedure for the synthesis of 2-amino-4-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-5-(4-substitutedphenyl)pyridine-3-carbonitrile (9a,b)
A mixture of compound 2 (2.83 g, 10 mmol), acetophenone and\or 4-methoxy acetophenone (10 mmol), malononitrile (10 mmol), ammonium acetate (11.2 g, 15 mmol), and Fe 3 O 4 (0.05 g) was heated under reflux in ethanol at 90 °C with stirring. The progress of the reaction was monitored by TLC (7:3, n-hexane/ethyl acetate). After completion of the reaction, the mixture was cooled to room temperature. Then the catalyst was separated from this mixture by filtration. The remaining solution is concentrated under reduced pressure to give the product as a crude. This crude was crystallized from ethanol.
2-amino-4-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-5-phenylpyridine-3-carbo-nitrile (9a)
2-amino-4-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-5-(4-methoxyphenyl) pyridine-3-carbonitrile (9b)
Pale 
(2E)-3-[3-(4-chlorophenyl) -1-phenyl -1H-pyrazol -4-yl] -2-(1H-tetrazol-5-yl)) prop-2-enenitrile (10)
Fe 3 O 4 (0.6 mmol) was added to a mixture of compound 2 (2.83 g, 10 mmol), malononitrile (0.66 g, 10 mmol), and NaN 3 (0.87 g, 12 mmol) in DMF (50 ml) stirred at 90°C for 8 h. After completion of the reaction. Aqueous HCl (2 N, 30 ml) was added to the filtrate with vigorous stirring, causing the product to precipitate. The precipitate was filtered and dried in a drying oven to furnish the tetrazoles. The product was crystallized from ethanol, as a red powder in 65 % yield; mp: 240-242°C; IR (KBr, cm 
Ethyl (2E)-3-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-yl]-2-cyanoprop-2-enoate (12)
To a solution of compound 2 (2.83 g, 10 mmol), ethyl cyanoacetate (1 ml, 7.5 mmol) and acetic acid (1.5 ml, 2.2 mmol) in dry toluene (30 mL) pyrrolidine (0.7 mmol) was added dropwise at room temperature and the mixture was refluxed for 5h . The reaction mixture was cooled to room temperature and the soild product was collected and crystallized from ethanol, as yellow solid in 90% yield mp 179-181 °C; IR (KBr, cm 
Ethyl 2-cyano-3-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-4-phenylbutanoate (13)
To a solution of compound 12 (3.78 mg, 10 mmol) in dry THF (30 mL) benzylmegansium bromide (10.4 mL, 10 mmol) was added and the reaction mixture was stirred under reflux for 6 h at 80 ᵒC. The reaction mixture was cooled to room temperature and the soild product was collected and crystallized from dioxane as a brown powder in 71% yield mp [195] [196] [197] 
3-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3, 4-dihydronaphthalen-1(2H)-one (15)
A suspension of compound 13 (2.28 mg, 5 mmol) in conc. HCl (20 mL) was refluxed for 5 h. The mixture was extracted by dichloromethane (50 mL) and washed with water (30 mL). The organic layer was dried over anhydrous MgSO 4 , filtered, and evaporated under reduced pressure. Then the crude 14 was added to trifluoroacetic anhydride (TFAA) (9 mL) at 0 °C. The mixture was stirred at room temperature for 7 h. 
Biological screening
In vitro anticancer activity. We evaluated the activity of newly synthesized compounds against the liver cancer (HepG2), human colonic carcinoma cell line (HCT-116), and human breast adenocarcinoma cell line (MCF-7) using the sulforhodamine B assay [18] . The three human cancer cell lines were provided by the National Cancer Institute (NCI, Cairo, Egypt). Continuous drug exposure for 48 h was the method used. All the cell lines were cultured in Dulbecco's modified Eagle's medium containing 10 % fetal bovine serum (FBS) (in a humidified atmosphere with 5 % CO 2 at 37 °C). Their growth as a monolayer was maintained in RPMI-1640 medium supplemented with 5 % heat inactivated FBS, 2 mmol L -1 glutamine and antibiotics (penicillin 100 U mL -1 , streptomycin 100 μg mL . The microtiter plates were incubated at 37 °C for 24 h prior to addition of experimental drugs and were incubated for 48 h with five different concentrations of each compound (0.01, 0.1, 1, 10, 100 μg mL -1 ), which were dissolved in DMSO and diluted with saline to the mentioned concentration, starting from a maximum concentration of 100 μg mL -1
. After 48 h, the cell monolayers were fixed by addition of 10 % (m/V) trichloroacetic acid and incubated at 4 °C for 1 h, and then stained for 30 min with 0.4 % (m/V) sulforhodamine B in 1 % acetic acid. Excess of unbound dye was removed by four washes with 1 % acetic acid and the attached stain was recovered with Tris-EDTA buffer. Absorbance was measured and growth inhibition of 50 % (GI 50 ) was calculated [19] . Table 1 displays GI 50 values of each compound for the above listed three cell lines. Doxorubicin was used as a reference compound. The influence of solvent, DMSO, on the growth of cell lines was evaluated in all experiments (negative control). This was performed by exposing untreated control cells to the maximum concentration of DMSO used in each assay (0.5 %).
Results and Discussion
Chemistry
The synthetic routes of the target compounds are outlined in Schemes 1-4. 3-(4-chlorophenyl)-1-phenyl -1H-pyrazol -4-carboxaldhyde 2 were prepared via acid condensation of 4-chloroacetophenone with phenylhydrazine hydrochloride afforded hydrazone derivative 1 which underwent cyclization following procedures applied in literature [17] Finally, the monoacid was accomplished by decarboxylation of 14 in situ with hydrochloric acid, which then underwent an intramolecular cyclization by using trifluoroacetic anhydride (TFAA) to give 3-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3,4-dihydronapthalene-1-(2H)-one 15 (Scheme 4).
Antitumor activity and structure activity relationship
The antitumor activity of the newly synthesized compounds was evaluated against three tumor cell lines namely liver cancer (HepG2), human colonic carcinoma cell line (HCT-116), and human breast adenocarcinoma cell line (MCF-7) after continuous exposure for 48 h. The results summarized in Table 1 show that most of the newly synthesized compounds exhibited significant antitumor activity compared to doxorubicin.
Pyrazole bearing 4-chlorophenyl thiazolidone 6d with GI 50 value of (0.01, 0.04 and 0.08 μmol L -1 ), and hexapyridodipyrimidine 11 moieties with GI 50 value of (0.01, 0.03 and 0.05 μmol ) against three tumor cell lines. Compound 6b exhibited good activity, while compounds 6a, c exhibited moderate activity the variation in activities may be due to the type of the substituent on the phenyl ring attached to thiazolidone moiety.
In addition, 4-fluorobenzyl-benzimidiazole 7b with GI 50 value of (0.01, 0.05 and 0.06 μmol L -1 ) exhibited higher antitumor activity than doxorubicin, the presence of stronger electronwithdrawing substituents (fluoro) in the paraposition of the phenyl ring might be responsible for enhancing the growth inhibition activity, while 4-chlorobenzyl-benzimidiazole 7c with GI 50 value of (0.05, 0.08 and 1.02 μmol L -1 ) is almost as active as doxorubicin. The absence of substituent in the phenyl ring as in compound 7a exhibited moderate activity. Compound 9b with GI 50 value of (0.09, 1.05 and 0.09 μmol L -1 ) revealed slightly lower activity than that of doxorubicin. On the other hand, compounds 3c exhibited moderate activity due to the presence of N-methyl imidiazole moiety. Furthermore, compounds 3b, 4, 5, 8, 9a, 10, 12 and 15 exhibited moderate to low antitumor activity on the three tumor cell lines, while compounds 3a exhibited very low antitumor activity.
Conclusions
We have synthesized novel pyrazole bearing thiazolyl, pyridinyl, imidiazolyl, tetrazolyl, and hexapyridodipyrimidine moieties, and were investigated for their anticancer activity.
Compounds 6d, 7b, c, 9b and 11 exhibited higher antitumor activity compared with Doxorubicin, while the other compounds showed good to moderate antitumor activity. The activity of these compounds are dependent on the pyrazole ring, the nature of heterocyclic ring, and the type of the substituent on the phenyl ring attached to these heterocyclic ring.
